Beyond androgen deprivation therapy: Next-generation hormonal therapies and emerging combination approaches in advanced prostate cancer

Urologic Oncology: Seminars and Original Investigations · Published 2026-08-01 · DOI 10.1016/j.urolonc.2026.07.014

Free full text

Authors (2)

Gabrielle Paras, Michael T. Schweizer

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Paras, G., Schweizer, M. (2026). Beyond androgen deprivation therapy: Next-generation hormonal therapies and emerging combination approaches in advanced prostate cancer. Urologic Oncology: Seminars and Original Investigations. https://doi.org/10.1016/j.urolonc.2026.07.014

Related articles

• Does size matter? A national analysis of patterns of adjuvant immunotherapy receipt and tumor size–dependent survival in pT3N0M0 clear cell renal cell carcinoma · Urologic Oncology: Seminars and Original Investigations · 2026 · Same journal
• Sex-based differences in peri-operative and long-term oncologic outcomes after primary surgical treatment for kidney cancer: A comprehensive analysis from a high-volume tertiary center · Urologic Oncology: Seminars and Original Investigations · 2026 · Same journal
• Universally offered germline testing in upper tract urothelial carcinoma · Urologic Oncology: Seminars and Original Investigations · 2026 · Same journal
• Automated algorithm for surgical outcomes abstraction for cystectomy · Urologic Oncology: Seminars and Original Investigations · 2026 · Same journal
• Post-treatment diffusion MRI–derived apparent diffusion coefficient as a biomarker of response and prognosis following definitive radiotherapy for prostate cancer: Impact of focal dose escalation on ADC dynamics · Urologic Oncology: Seminars and Original Investigations · 2026 · Same journal
• Beyond PSA90: Deep PSA response predicts outcomes in nonmetastatic CRPC · Urologic Oncology: Seminars and Original Investigations · 2026 · Same journal
• Clinical outcomes of deferred cytoreductive nephrectomy after initial systemic therapy in metastatic renal cell carcinoma: A multicenter retrospective study · Urologic Oncology: Seminars and Original Investigations · 2026 · Same journal
• Association of EVITA with safety in advanced urothelial carcinoma: A multicenter real-world study · Urologic Oncology: Seminars and Original Investigations · 2026 · Same journal
• Featured SUO Fellow: Parth Thakker, MD · Urologic Oncology: Seminars and Original Investigations · 2026 · Same journal
• Identification and validation of TP53/p53 status as a prognostic marker in penile squamous cell carcinoma: Evidence from a cohort study and meta-analysis · Urologic Oncology: Seminars and Original Investigations · 2026 · Same journal